alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
"['L2427Q', 'L2209V']","[{'ncitCode': 'C1844', 'drugName': 'Temsirolimus'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 875, 'code': '', 'color': 'Orange', 'name': '', 'mainType': {'id': None, 'name': 'Renal Cell Carcinoma', 'tumorForm': 'SOLID'}, 'tissue': 'Kidney', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['26831717'],[],"Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) that is NCCN-listed and FDA-approved for patients with advanced renal cell carcinoma (RCC). In a study of 79 patients with metastatic RCC who were treated with mTOR inhibitors and who underwent targeted next-generation sequencing, mutations in MTOR (L2427Q and L2209V, n = 1, respectively), TSC1 or TSC2 were more common in responders, (12/43 patients, 28%) than non-responders (4/36 patients, 11%) (p=0.06) and 5/12 patients (42%) with partial responses had mutations in these genes compared to 4/36 (11%) non-responders (p=0.03) (PMID: 26831717)."
['Oncogenic Mutations'],"[{'ncitCode': 'C48387', 'drugName': 'Everolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
['Oncogenic Mutations'],"[{'ncitCode': 'C1844', 'drugName': 'Temsirolimus'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['24631838', '27482884', '30327302', '26831717', '24622468']",[],"Everolimus and temsirolimus are inhibitors of the mammalian target of rapamycin (mTOR) that are FDA-approved for patients with advanced renal cell carcinoma (RCC). Retrospective studies of mTOR inhibitors in patients with metastatic renal cell carcinoma indicate that mutations in TSC1, TSC2, and mTOR are associated with response to treatment (PMID: 24622468, 26831717). Preclinical studies show that cancer cell lines with hyperactivating mTOR mutations are sensitive to mTOR inhibitor treatment as measured by decreased proliferation in cell line and xenograft experiments (PMID: 24631838, 27482884). However, one analysis of the RECORD-3 trial has indicated that PTEN status versus mTOR, TSC1 or TSC2 status may be the major correlative in response to treatment with everolimus (PMID: 30327302)."
